Literature DB >> 11895882

The expression of a variant prostate-specific antigen in human prostate.

Fan J Meng1, Ailin Shan, Long Jin, Charles Y F Young.   

Abstract

Although a splicing variant of prostate specific antigen (PSA-v) mRNA has been described previously, whether its protein (PSA-v or PSA-related protein 1, i.e., PSA-RP1) is actually expressed in human prostate cells remains elusive. We report that PSA-v protein is expressed in prostatic epithelia of both cancerous and benign tissues. Also, secreted PSA-v can be detected in the medium of a prostate cancer (PCa) cell line. Consistently, PSA-v mRNA is exclusively expressed in benign luminal epithelia and cancer cells of the prostate by in situ hybridization. Northern analysis of a cohort of 51 pairs of RNA samples from microdissected tissues showed that PSA-v mRNA levels remained constant in both benign and cancerous tissues, whereas PSA levels declined in cancerous areas. Our result suggests that it would be feasible to develop proper immunoassays for PSA-v to test whether PSA-v could have some clinical utility.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895882

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  5 in total

1.  Identification of Clinically Significant Prostate Cancer by Combined PCA3 and AMACR mRNA Detection in Urine Samples.

Authors:  Elena S Kotova; Yulia A Savochkina; Yuriy V Doludin; Alexander O Vasilyev; Elena A Prilepskay; Natalia V Potoldykova; Konstantin A Babalyan; Alexandra V Kanygina; Andrey O Morozov; Alexander V Govorov; Dmitry V Enikeev; Elena S Kostryukova; Elena N Ilina; Vadim M Govorun; Dmitry Y Pushkar; Elena I Sharova
Journal:  Res Rep Urol       Date:  2020-09-17

Review 2.  The use of PCA3 in the diagnosis of prostate cancer.

Authors:  Daphne Hessels; Jack A Schalken
Journal:  Nat Rev Urol       Date:  2009-05       Impact factor: 14.432

3.  Prostate-specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria.

Authors:  Emeka I Udeh; Ikenna I Nnabugwu; Francis O Ozoemena; Fred O Ugwumba; Adesina S O Aderibigbe; Samuel R Ohayi; Kevin N Echetabu
Journal:  World J Surg Oncol       Date:  2016-06-29       Impact factor: 2.754

4.  Is there any association between National Institute of Health category IV prostatitis and prostate-specific antigen levels in patients with low-risk localized prostate cancer?

Authors:  Omer Gokhan Doluoglu; Cavit Ceylan; Fatih Kilinc; Eymen Gazel; Berkan Resorlu; Oner Odabas
Journal:  Int Braz J Urol       Date:  2016 Mar-Apr       Impact factor: 1.541

5.  High-Intensity Focused Ultrasound (HIFU) Focal Therapy for Localized Prostate Cancer with MRI-US Fusion Platform.

Authors:  Chi-Hang Yee; Peter Ka-Fung Chiu; Jeremy Yuen-Chun Teoh; Chi-Fai Ng; Chi-Kwok Chan; See-Ming Hou
Journal:  Adv Urol       Date:  2021-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.